Genfit S.A. (GNFT.PA) Stock

About Genfit S.A.

Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.

Genfit S.A. is led by CEO Pascal Prigent, employs 161 people, headquartered in Loos, FR, publicly traded since 2006.

over the past 52 weeks the stock has ranged between $3.05 and $15.48, and currently trades 15.9% below its 52-week high.

Official website: www.genfit.com